Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 63

1.

Patterns of systemic and local inflammation in patients with asthma hospitalised with influenza.

Jha A, Dunning J, Tunstall T, Thwaites RS, Hoang LT; MOSAIC Investigators, Kon OM, Zambon MC, Hansel TT, Openshaw PJ.

Eur Respir J. 2019 Oct 24;54(4). pii: 1900949. doi: 10.1183/13993003.00949-2019. Print 2019 Oct.

PMID:
31391224
2.

Author Correction: Progression of whole-blood transcriptional signatures from interferon-induced to neutrophil-associated patterns in severe influenza.

Dunning J, Blankley S, Hoang LT, Cox M, Graham CM, James PL, Bloom CI, Chaussabel D, Banchereau J, Brett SJ; MOSAIC Investigators, Moffatt MF, O'Garra A, Openshaw PJM.

Nat Immunol. 2019 Mar;20(3):373. doi: 10.1038/s41590-019-0328-y.

3.

Progression of whole-blood transcriptional signatures from interferon-induced to neutrophil-associated patterns in severe influenza.

Dunning J, Blankley S, Hoang LT, Cox M, Graham CM, James PL, Bloom CI, Chaussabel D, Banchereau J, Brett SJ, Moffatt MF, O'Garra A, Openshaw PJM; MOSAIC Investigators.

Nat Immunol. 2018 Jun;19(6):625-635. doi: 10.1038/s41590-018-0111-5. Epub 2018 May 18. Erratum in: Nat Immunol. 2019 Mar;20(3):373.

4.

The UK's multidisciplinary response to an Ebola epidemic.

Reece S, Brown CS, Dunning J, Chand MA, Zambon MC, Jacobs M.

Clin Med (Lond). 2017 Jul;17(4):332-337. doi: 10.7861/clinmedicine.17-4-332.

5.

Influenza vaccine: going through a sticky patch.

Höschler K, Zambon MC.

Lancet. 2017 Aug 12;390(10095):627-628. doi: 10.1016/S0140-6736(17)31364-8. Epub 2017 Jun 27. No abstract available.

PMID:
28666679
6.

Is the onset of influenza in the community age-related?

Fleming DM, Durnall H, Warburton F, Ellis JS, Zambon MC.

Epidemiol Infect. 2016 Aug;144(11):2295-305. doi: 10.1017/S0950268816000510.

PMID:
27350234
7.

Surveillance for antiviral resistance.

Zambon MC.

Influenza Other Respir Viruses. 2013 Jan;7 Suppl 1:37-43. doi: 10.1111/irv.12050.

8.

Evaluation of influenza virus antiviral susceptibility testing in Europe: results from the first external quality assessment exercise.

Thompson CI, Lackenby A, Daniels RS, McCauley JW, Pereyaslov D, Broberg EK, Meijer A, Zambon MC.

J Clin Virol. 2013 Mar;56(3):212-8. doi: 10.1016/j.jcv.2012.11.005. Epub 2012 Nov 30.

PMID:
23201459
9.

IFITM3 restricts the morbidity and mortality associated with influenza.

Everitt AR, Clare S, Pertel T, John SP, Wash RS, Smith SE, Chin CR, Feeley EM, Sims JS, Adams DJ, Wise HM, Kane L, Goulding D, Digard P, Anttila V, Baillie JK, Walsh TS, Hume DA, Palotie A, Xue Y, Colonna V, Tyler-Smith C, Dunning J, Gordon SB; GenISIS Investigators; MOSAIC Investigators, Smyth RL, Openshaw PJ, Dougan G, Brass AL, Kellam P.

Nature. 2012 Mar 25;484(7395):519-23. doi: 10.1038/nature10921.

10.

Reproducibility of serology assays for pandemic influenza H1N1: collaborative study to evaluate a candidate WHO International Standard.

Wood JM, Major D, Heath A, Newman RW, Höschler K, Stephenson I, Clark T, Katz JM, Zambon MC.

Vaccine. 2012 Jan 5;30(2):210-7. doi: 10.1016/j.vaccine.2011.11.019. Epub 2011 Nov 17.

PMID:
22100887
11.

Fatal cases of influenza a in childhood.

Johnson BF, Wilson LE, Ellis J, Elliot AJ, Barclay WS, Pebody RG, McMenamin J, Fleming DM, Zambon MC.

PLoS One. 2009 Oct 30;4(10):e7671. doi: 10.1371/journal.pone.0007671.

12.

Safety and immunogenicity of whole-virus, alum-adjuvanted whole-virus, virosomal, and whole-virus intradermal influenza A/H9N2 vaccine formulations.

Nicholson KG, Thompson CI, Klap JM, Wood JM, Batham S, Newman RW, Mischler R, Zambon MC, Stephenson I.

Vaccine. 2009 Dec 10;28(1):171-8. doi: 10.1016/j.vaccine.2009.09.103. Epub 2009 Sep 30.

PMID:
19799843
13.

Reproducibility of serologic assays for influenza virus A (H5N1).

Stephenson I, Heath A, Major D, Newman RW, Hoschler K, Junzi W, Katz JM, Weir JP, Zambon MC, Wood JM.

Emerg Infect Dis. 2009 Aug;15(8):1252-9. doi: 10.3201/eid1508.081754.

14.

Antigenically distinct MF59-adjuvanted vaccine to boost immunity to H5N1.

Stephenson I, Nicholson KG, Hoschler K, Zambon MC, Hancock K, DeVos J, Katz JM, Praus M, Banzhoff A.

N Engl J Med. 2008 Oct 9;359(15):1631-3. doi: 10.1056/NEJMc0805274. No abstract available.

PMID:
18843132
15.

Rapid quantitation of neuraminidase inhibitor drug resistance in influenza virus quasispecies.

Lackenby A, Democratis J, Siqueira MM, Zambon MC.

Antivir Ther. 2008;13(6):809-20.

PMID:
18839782
16.

Safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in infants and children.

Nolan T, Richmond PC, Formica NT, Höschler K, Skeljo MV, Stoney T, McVernon J, Hartel G, Sawlwin DC, Bennet J, Ryan D, Basser RL, Zambon MC.

Vaccine. 2008 Nov 25;26(50):6383-91. doi: 10.1016/j.vaccine.2008.08.046. Epub 2008 Sep 16.

PMID:
18801398
17.

Phase I and II randomised trials of the safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in healthy adults.

Nolan TM, Richmond PC, Skeljo MV, Pearce G, Hartel G, Formica NT, Höschler K, Bennet J, Ryan D, Papanaoum K, Basser RL, Zambon MC.

Vaccine. 2008 Aug 5;26(33):4160-7. doi: 10.1016/j.vaccine.2008.05.077. Epub 2008 Jun 13.

PMID:
18599164
18.

Emergence of resistance to oseltamivir among influenza A(H1N1) viruses in Europe.

Lackenby A, Hungnes O, Dudman SG, Meijer A, Paget WJ, Hay AJ, Zambon MC.

Euro Surveill. 2008 Jan 31;13(5). pii: 8026. No abstract available.

19.

Influenza and respiratory syncytial virus infections in British Hajj pilgrims.

Rashid H, Shafi S, Booy R, El Bashir H, Ali K, Zambon M, Memish Z, Ellis J, Coen P, Haworth E.

Emerg Health Threats J. 2008;1:e2. doi: 10.3134/ehtj.08.002. Epub 2008 Feb 29.

20.

Establishment of a UK National Influenza H5 Laboratory Network.

Curran MD, Ellis JS, Wreghitt TG, Zambon MC.

J Med Microbiol. 2007 Oct;56(Pt 10):1263-7. Review.

PMID:
17893159
21.

Cross-neutralisation of antibodies elicited by an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine in healthy adults against H5N1 clade 2 strains.

Höschler K, Gopal R, Andrews N, Saville M, Pepin S, Wood J, Zambon MC.

Influenza Other Respir Viruses. 2007 Sep-Nov;1(5-6):199-206. doi: 10.1111/j.1750-2659.2007.00033.x.

22.

Generation of candidate human influenza vaccine strains in cell culture - rehearsing the European response to an H7N1 pandemic threat.

Whiteley A, Major D, Legastelois I, Campitelli L, Donatelli I, Thompson CI, Zambon MC, Wood JM, Barclay WS.

Influenza Other Respir Viruses. 2007 Jul;1(4):157-66. doi: 10.1111/j.1750-2659.2007.00022.x.

23.
24.

Infection of human airway epithelium by human and avian strains of influenza a virus.

Thompson CI, Barclay WS, Zambon MC, Pickles RJ.

J Virol. 2006 Aug;80(16):8060-8.

25.

Modelling hospital admissions for lower respiratory tract infections in the elderly in England.

Müller-Pebody B, Crowcroft NS, Zambon MC, Edmunds WJ.

Epidemiol Infect. 2006 Dec;134(6):1150-7. Epub 2006 May 26. Review.

26.

Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial.

Bresson JL, Perronne C, Launay O, Gerdil C, Saville M, Wood J, Höschler K, Zambon MC.

Lancet. 2006 May 20;367(9523):1657-64.

PMID:
16714186
27.

Phase I evaluation of intranasal trivalent inactivated influenza vaccine with nontoxigenic Escherichia coli enterotoxin and novel biovector as mucosal adjuvants, using adult volunteers.

Stephenson I, Zambon MC, Rudin A, Colegate A, Podda A, Bugarini R, Del Giudice G, Minutello A, Bonnington S, Holmgren J, Mills KH, Nicholson KG.

J Virol. 2006 May;80(10):4962-70.

28.

Rates of hospitalisation for influenza, respiratory syncytial virus and human metapneumovirus among infants and young children.

Nicholson KG, McNally T, Silverman M, Simons P, Stockton JD, Zambon MC.

Vaccine. 2006 Jan 9;24(1):102-8. Epub 2005 Feb 25.

PMID:
16310899
29.

Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy.

Stephenson I, Bugarini R, Nicholson KG, Podda A, Wood JM, Zambon MC, Katz JM.

J Infect Dis. 2005 Apr 15;191(8):1210-5. Epub 2005 Mar 14.

PMID:
15776364
30.

Longitudinally profiling neutralizing antibody response to SARS coronavirus with pseudotypes.

Temperton NJ, Chan PK, Simmons G, Zambon MC, Tedder RS, Takeuchi Y, Weiss RA.

Emerg Infect Dis. 2005 Mar;11(3):411-6.

31.

Ethics versus evidence in influenza vaccination.

Zambon MC.

Lancet. 2004 Dec 18-31;364(9452):2161-3. No abstract available.

PMID:
15610788
32.

Laboratory diagnosis of SARS.

Bermingham A, Heinen P, Iturriza-Gómara M, Gray J, Appleton H, Zambon MC.

Philos Trans R Soc Lond B Biol Sci. 2004 Jul 29;359(1447):1083-9. Review.

33.

Confronting the avian influenza threat: vaccine development for a potential pandemic.

Stephenson I, Nicholson KG, Wood JM, Zambon MC, Katz JM.

Lancet Infect Dis. 2004 Aug;4(8):499-509. Review.

PMID:
15288823
34.

Detection of anti-H5 responses in human sera by HI using horse erythrocytes following MF59-adjuvanted influenza A/Duck/Singapore/97 vaccine.

Stephenson I, Wood JM, Nicholson KG, Charlett A, Zambon MC.

Virus Res. 2004 Jul;103(1-2):91-5.

PMID:
15163495
35.

Influenza virological surveillance in children: the use of the QuickVue rapid diagnostic test.

Pregliasco F, Puzelli S, Mensi C, Anselmi G, Marinello R, Tanzi ML, Affinito C, Zambon MC, Donatelli I; Collaborative Group Influchild.

J Med Virol. 2004 Jun;73(2):269-73.

PMID:
15122803
36.

Changes in in vitro susceptibility of influenza A H3N2 viruses to a neuraminidase inhibitor drug during evolution in the human host.

Thompson CI, Barclay WS, Zambon MC.

J Antimicrob Chemother. 2004 May;53(5):759-65. Epub 2004 Mar 17.

PMID:
15028666
37.

Can a short period of micronutrient supplementation in older institutionalized people improve response to influenza vaccine? A randomized, controlled trial.

Allsup SJ, Shenkin A, Gosney MA, Taylor S, Taylor W, Hammond M, Zambon MC.

J Am Geriatr Soc. 2004 Jan;52(1):20-4.

PMID:
14687310
38.

Safety and antigenicity of whole virus and subunit influenza A/Hong Kong/1073/99 (H9N2) vaccine in healthy adults: phase I randomised trial.

Stephenson I, Nicholson KG, Glück R, Mischler R, Newman RW, Palache AM, Verlander NQ, Warburton F, Wood JM, Zambon MC.

Lancet. 2003 Dec 13;362(9400):1959-66.

PMID:
14683655
39.

Influenza-related hospitalizations among young children in Leicestershire.

Nicholson KG, McNally T, Silverman M, Simons P, Zambon MC.

Pediatr Infect Dis J. 2003 Oct;22(10 Suppl):S228-30.

PMID:
14551481
40.

Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome.

Kuiken T, Fouchier RA, Schutten M, Rimmelzwaan GF, van Amerongen G, van Riel D, Laman JD, de Jong T, van Doornum G, Lim W, Ling AE, Chan PK, Tam JS, Zambon MC, Gopal R, Drosten C, van der Werf S, Escriou N, Manuguerra JC, Stöhr K, Peiris JS, Osterhaus AD.

Lancet. 2003 Jul 26;362(9380):263-70.

PMID:
12892955
41.

Three years of low influenza activity--no reason for complacency.

Goddard NL, Joseph CA, Watson JM, Ellis JS, Zambon MC.

Commun Dis Public Health. 2003 Jun;6(2):128-32.

PMID:
12889292
42.

Sialic acid receptor specificity on erythrocytes affects detection of antibody to avian influenza haemagglutinin.

Stephenson I, Wood JM, Nicholson KG, Zambon MC.

J Med Virol. 2003 Jul;70(3):391-8.

PMID:
12767002
43.

Influenza AH1N2 viruses, United Kingdom, 2001-02 influenza season.

Ellis JS, Alvarez-Aguero A, Gregory V, Lin YP, Hay A, Zambon MC.

Emerg Infect Dis. 2003 Mar;9(3):304-10.

44.

Molecular diagnosis of influenza.

Ellis JS, Zambon MC.

Rev Med Virol. 2002 Nov-Dec;12(6):375-89. Review.

PMID:
12410529
45.

Contribution of RSV to bronchiolitis and pneumonia-associated hospitalizations in English children, April 1995-March 1998.

Müller-Pebody B, Edmunds WJ, Zambon MC, Gay NJ, Crowcroft NS.

Epidemiol Infect. 2002 Aug;129(1):99-106.

46.

Contribution of influenza and respiratory syncytial virus to community cases of influenza-like illness: an observational study.

Zambon MC, Stockton JD, Clewley JP, Fleming DM.

Lancet. 2001 Oct 27;358(9291):1410-6.

PMID:
11705487
48.

Detection of influenza a subtypes in community-based surveillance.

Boon AC, French AM, Fleming DM, Zambon MC.

J Med Virol. 2001 Sep;65(1):163-70.

PMID:
11505459
49.

The pathogenesis of influenza in humans.

Zambon MC.

Rev Med Virol. 2001 Jul-Aug;11(4):227-41. Review.

PMID:
11479929
50.

Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza.

Nicholson KG, Colegate AE, Podda A, Stephenson I, Wood J, Ypma E, Zambon MC.

Lancet. 2001 Jun 16;357(9272):1937-43.

PMID:
11425416

Supplemental Content

Loading ...
Support Center